{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:56:54Z","timestamp":1793156214603,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.diagmicrobio.2020.115108","type":"journal-article","created":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T19:19:28Z","timestamp":1592075968000},"page":"115108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Frequency and antimicrobial susceptibility of bacteria causing bloodstream infections in pediatric patients from United States (US) medical centers (2014\u20132018): therapeutic options for multidrug-resistant bacteria"],"prefix":"10.1016","volume":"98","author":[{"given":"Helio S.","family":"Sader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Streit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia G.","family":"Carvalhaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2020.115108_bb0005","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1017\/S0950268810001640","article-title":"Epidemiology and outcome of Gram-negative bloodstream infection in children: a population-based study","volume":"139","author":"Al-Hasan","year":"2011","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.diagmicrobio.2020.115108_bb0010","unstructured":"AVYCAZ\u00ae AVYCAZ\u00ae (ceftazidime-avibactam). 2019 Available at https:\/\/www.allergan.com\/assets\/pdf\/avycaz_pi February 2020"},{"key":"10.1016\/j.diagmicrobio.2020.115108_bb0015","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/INF.0000000000002395","article-title":"Safety and efficacy of ceftazidime-avibactam in the treatment of children \u22653 months to <18 years with complicated urinary tract infection: results from a phase 2 randomized, controlled trial","volume":"38","author":"Bradley","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.diagmicrobio.2020.115108_bb0020","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/ofid\/ofy347","article-title":"Variations in the occurrence of resistance phenotypes and carbapenemase genes among Enterobacteriaceae isolates in 20 years of the SENTRY antimicrobial surveillance program","volume":"6","author":"Castanheira","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2020.115108_bb0025","author":"CDC"},{"key":"10.1016\/j.diagmicrobio.2020.115108_bb0030","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: eleventh edition","article-title":"M07Ed11","author":"CLSI","year":"2018"},{"key":"10.1016\/j.diagmicrobio.2020.115108_bb0035","series-title":"Performance standards for antimicrobial susceptibility testing: 29th informational supplement","article-title":"M100Ed29","author":"CLSI","year":"2019"},{"key":"10.1016\/j.diagmicrobio.2020.115108_bb0040","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00355-19","article-title":"The microbiology of bloodstream infection: 20-year trends from the SENTRY antimicrobial surveillance program","volume":"63","author":"Diekema","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115108_bb0045","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/INF.0000000000002344","article-title":"Use of ceftazidime-avibactam for the treatment of extensively drug-resistant or pan drug-resistant Klebsiella pneumoniae in neonates and children <5 years of age","volume":"38","author":"Iosifidis","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.diagmicrobio.2020.115108_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/ice.2017.236","article-title":"Pathogen distribution and antimicrobial resistance among pediatric healthcare-associated infections reported to the National Healthcare Safety Network, 2011\u20132014","volume":"39","author":"Lake","year":"2018","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.diagmicrobio.2020.115108_bb0055","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1586\/14787210.2015.1063418","article-title":"Bacteremia in children: epidemiology, clinical diagnosis and antibiotic treatment","volume":"13","author":"Pai","year":"2015","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.diagmicrobio.2020.115108_bb0060","doi-asserted-by":"crossref","first-page":"114850","DOI":"10.1016\/j.diagmicrobio.2019.06.002","article-title":"Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bloodstream infections in United States medical centers (2015\u20132017)","volume":"95","author":"Sader","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2020.115108_bb0065","doi-asserted-by":"crossref","unstructured":"Sader, H.S., Flamm, R.K., Carvalhaes, C.G., & Castanheira, M. (2018) Antimicrobial susceptibility of Pseudomonas aeruginosa to ceftazidime-avibactam, ceftolozane-tazobactam, piperacillin-tazobactam, and meropenem stratified by U.S. census divisions: results from the 2017 INFORM Program. Antimicrob Agents Chemother, 62: e01587.","DOI":"10.1128\/AAC.01587-18"},{"key":"10.1016\/j.diagmicrobio.2020.115108_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227139","article-title":"Impact of multi-drug resistant bacteria on economic and clinical outcomes of healthcare-associated infections in adults: systematic review and meta-analysis","volume":"15","author":"Serra-Burriel","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.diagmicrobio.2020.115108_bb0075","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/joim.12342","article-title":"Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control","volume":"277","author":"Tangden","year":"2015","journal-title":"J Intern Med"},{"key":"10.1016\/j.diagmicrobio.2020.115108_bb0080","doi-asserted-by":"crossref","DOI":"10.1097\/INF.0000000000002669","article-title":"Epidemiology, clinical and microbiologic profile and risk factors for inpatient mortality in pediatric severe sepsis in the United States from 2003 to 2014: a large population analysis","author":"Thavamani","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.diagmicrobio.2020.115108_bb0085","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1017\/ice.2016.174","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011\u20132014","volume":"37","author":"Weiner","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.diagmicrobio.2020.115108_bb0090","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1017\/ice.2019.297","article-title":"Antimicrobial-resistant pathogens associated with pediatric healthcare-associated infections: summary of data reported to the National Healthcare Safety Network, 2015\u20132017","volume":"41","author":"Weiner-Lastinger","year":"2020","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.diagmicrobio.2020.115108_bb0095","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","article-title":"Ceftazidime-avibactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination","volume":"73","author":"Zhanel","year":"2013","journal-title":"Drugs"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889320304855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889320304855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:54:09Z","timestamp":1760003649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889320304855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0732889320304855"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2020.115108","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frequency and antimicrobial susceptibility of bacteria causing bloodstream infections in pediatric patients from United States (US) medical centers (2014\u20132018): therapeutic options for multidrug-resistant bacteria","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2020.115108","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115108"}}